Synoptical view

    Stock
    Abivax is listed on EURONEXT GROWTH PARIS since june 2015
    Truffle investment
    € 32m
abivax_xbx64.jpg

Management team

hartmut_ehrlich.jpg

Prof. Hartmut Ehrlich

CEO

didier_blondel.jpg

Didier Blondel

CFO

Board of Directors

joy_amundson.jpg

Joy Amundson

Partners

cnrs.png

In summary

Truffle Capital has created and invested in Abivax to develop two unique platforms that address huge medical needs and a multi-billion dollar market: viral diseases, particularly HIV/AIDS, inflammatory diseases, including digestive system diseases and liver cancer.

They talk about it

hartmut_ehrlich.jpg

Abivax made excellent progress during the first half of 2019 by accelerating the clinical development of its drug candidates while successfully raising funds from Sofinnova Partners in July 2019. This financing from a recognized investor in the life sciences extends our cash flow coverage to the end of the second quarter of 2020 and validates the relevance of our scientific approach and strategy

Media

News

News
880_ceoradio.jpg

"19 Hours a day of COVID-19" live the quarantine with Hartmut J. Ehrlich and Philippe Pouletty. A Truffle Capital mini-serie

actility_start_up_bretonne_01.jpg

Next start-up

Actility